Central serous chorioretinopathy imaging biomarkers.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
04 2022
Historique:
received: 06 07 2020
revised: 21 10 2020
accepted: 18 11 2020
pubmed: 9 12 2020
medline: 3 5 2022
entrez: 8 12 2020
Statut: ppublish

Résumé

To identify the factors predicting the visual and anatomical outcomes in eyes with central serous chorioretinopathy (CSCR) through 12 months. Patients with diagnosis of CSCR, either acute or chronic, were included in this multicentric, retrospective study. Demographic factors; systemic risk factors; central macular thickness (CMT), subfoveal choroidal thickness (SFCT), linear extent of ellipsoid zone (EZ) and interdigitation zone damage on optical coherence tomography; details of leak on fluorescein angiography and indocyanine green angiography were included as predictors of anatomical and visual outcomes. Regression analysis was performed to correlate the changes in best corrected visual acuity (BCVA) and resolution of disease activity. A total of 231 eyes of 201 patients with a mean age (49.7±11.8 years) were analysed. A total of 97 and 134 eyes were classified as acute and chronic CSCR. BCVA (0.35±0.31 to 0.24±0.34; p<0.001), baseline optical coherence tomography (OCT) parameters including CMT (p<0.001), subretinal fluid (SRF) height (p<0.001) and SFCT (p=0.05) showed a significant change through 12 months. Multivariate regression analysis showed change in CMT (p≤0.01) and SRF height at baseline (p=0.05) as factors predictive of good visual outcome. Logistic regression analysis revealed changes in both CMT (p=0.009) and SFCT (p=0.01) through 12 months to correlate with the resolution of disease. OCT parameters such as changes in both CMT and SFCT along with subfoveal EZ damage can be predictive of disease resolution whereas changes in CMT and baseline SRF height correlate well with changes in BCVA through 12 months.

Identifiants

pubmed: 33288526
pii: bjophthalmol-2020-317422
doi: 10.1136/bjophthalmol-2020-317422
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

553-558

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Sumit Randhir Singh (SR)

Jacobs Retina Center, University of California San Diego, La Jolla, California, USA.

Claudio Iovino (C)

Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.

Dinah Zur (D)

Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dua Masarwa (D)

Department of Ophthalmology, Barzilai University Medical Center, Ashkelon, Israel.

Matias Iglicki (M)

Private Retina Service, University of Buenos Aires, Buenos Aires, Argentina.

Ramkailash Gujar (R)

Department of Surgical and Biomedical Sciences, Section of Ophthalmology, University of Perugia, Perugia, Italy.

Marco Lupidi (M)

Department of Ophthalmology, University of Perugia, Perugia, Italy.

Dmitrii S Maltsev (DS)

Ophthalmology, Military Maedical Academy, Saint Petersburg, Russian Federation.

Elodie Bousquet (E)

Ophthalmology, Hopital Cochin, Paris, France.

Mehdi Bencheqroun (M)

Ophtalmopôle, Cochin Hospital, Paris Descartes University, Paris, France.

Francesca Amoroso (F)

Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Université Paris Est, Creteil, France.

Luiz H Lima (LH)

Ophthalmology, Federal University of Sao Paulo, São Paulo, Brazil.

Srikanta Kumar Padhy (SK)

Ophthalmology, AIIMS, New Delhi, India.

Vishal Govindahari (V)

Retina and Uveitis Service, L V Prasad Eye Institute, MTC Campus, Bhubaneswar, India.

Khushboo Chandra (K)

Dept. of Vitreoretina, Disha Eye Hospitals Pvt Ltd, Kolkata, India.

Eric H Souied (EH)

Ophthalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France.

Francisco J Rodriguez (FJ)

Fundacion Oftalmologica Nacional, Universidad del Rosario, Bogota, Colombia.

Laura A Daza (LA)

Fundacion Oftalmologica Nacional, Universidad del Rosario, Bogota, Colombia.

Hernan A Rios (HA)

Fundacion Oftalmologica Nacional, Universidad del Rosario, Bogota, Colombia.

Carlo Cagini (C)

Department of Biomedical and Surgical Sciences, University of Perugia School of Medicine and Surgery, Perugia, Italy.

Enrico Peiretti (E)

Eye Clinic, Universita degli Studi di Cagliari, Cagliari, Italy.

Francine Behar-Cohen (F)

Team 17, INSERM UMR1138, Paris, France.

Jay Chhablani (J)

UPMC Eye Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA jay.chhablani@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH